| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Purple Biotech Ltd reports results for the quarter ended in January - Earnings Summary | 2 | Reuters | ||
| Di | Purple Biotech GAAP EPADS of -$0.14 beats by $0.05 | 2 | Seeking Alpha | ||
| Di | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Di | Purple Biotech Ltd.: Purple Biotech Reports First Quarter 2024 Financial Results | 122 | GlobeNewswire (Europe) | REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness... ► Artikel lesen | |
| 25.04. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.04. | Purple Biotech Ltd.: Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting | 69 | GlobeNewswire (Europe) | Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple... ► Artikel lesen | |
| 28.03. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 14.03. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 14.03. | Purple Biotech Ltd.: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology | 362 | GlobeNewswire (Europe) | Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which... ► Artikel lesen | |
| 05.03. | PURPLE BIOTECH LTD. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 05.03. | Purple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results | 456 | GlobeNewswire (Europe) | REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness... ► Artikel lesen | |
| 05.03. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 27.02. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 27.02. | Purple Biotech Ltd.: Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 | 347 | GlobeNewswire (Europe) | NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024 (GLOBE... ► Artikel lesen | |
| 13.02. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 13.02. | Purple Biotech Ltd.: Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial | 1 | GlobeNewswire (USA) | ||
| 01.02. | Purple Biotech stock climbs 9% on Phase 2 study update | 3 | Seeking Alpha | ||
| 01.02. | Purple Biotech sets phase 2 dose for cancer drug NT219 | 2 | Investing.com | ||
| 01.02. | Purple Biotech Ltd.: Purple Biotech Reaches Recommended Phase 2 Dose for NT219 | 198 | GlobeNewswire (Europe) | REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness... ► Artikel lesen | |
| 26.01. | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NEL | 2.073 |
| GAMESTOP | 2.026 |
| NVIDIA | 1.962 |
| EVOTEC | 1.836 |
| TUI | 1.146 |
| BAYER | 954 |
| BIONTECH | 745 |
| PLUG POWER | 611 |
| RHEINMETALL | 596 |
| DEUTSCHE LUFTHANSA | 516 |
| VOLKSWAGEN | 482 |
| SUPER MICRO COMPUTER | 481 |
| BYD | 460 |
| SIEMENS ENERGY | 455 |
| COMMERZBANK | 444 |
| MERCEDES-BENZ | 419 |
| TESLA | 393 |
| DEUTSCHE BANK | 379 |
| HEIDELBERGER DRUCK | 353 |
| AIXTRON SE | 348 |
| RWE | 338 |
| ADLER GROUP | 332 |
| BASF | 319 |
| AMC ENTERTAINMENT | 318 |
| RENK GROUP | 317 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
